文献速递系统性红斑狼疮

绝经激素治疗对系统性红斑狼疮风险的影响:韩国全国性队列研究

The effects of menopausal hormone therapy for the risk of systemic lupus erythematosus: A nationwide cohort study in Korea.
PubMed 文献 · Semin Arthritis Rheum · 2025-01-30

该回顾性队列研究基于韩国2011年1月1日至2014年12月31日40岁以上因绝经就诊女性452,124例,倾向评分匹配后纳入139,331对,随访至2020年12月31日。中位随访7.9年,绝经激素治疗(MHT)组与非MHT组系统性红斑狼疮(SLE)风险无显著增加(HR 1.114,95%CI 0.88-1.41)。亚组分析除替勃龙外,MHT类型或使用时长均无显著差异;使用替勃龙3年以内者SLE风险HR为1.45(95%CI 1.051-2.001)。

要点

  • MHT组SLE风险较非MHT组无显著增加(HR 1.114,95%CI 0.88-1.41)。
  • 除替勃龙外,MHT类型或使用时长对SLE风险无显著差异。
  • 替勃龙使用3年以内者SLE风险升高(HR 1.45,95%CI 1.051-2.001)。

核心结论

  • MHT对绝经后女性SLE的发生无实质影响;替勃龙使用早期需谨慎。

研究设计与样本

  • 韩国全国性回顾性队列研究,2011年1月1日至2014年12月31日纳入40岁以上因绝经就诊女性452,124例,倾向评分匹配后纳入139,331对,随访至2020年12月31日。

主要发现

  • 中位随访7.9年(范围6.9-8.9年),MHT组139,197例中134例(0.1%)发生SLE,非MHT组139,188例中143例(0.1%)发生SLE。
  • MHT组较非MHT组SLE风险无显著增加(HR 1.114,95%CI 0.88-1.41)。
  • 亚组分析显示除替勃龙外,MHT类型或使用时长对SLE风险无显著差异;替勃龙使用3年以内者SLE风险HR为1.45(95%CI 1.051-2.001)。

关键数值与推荐

  • SLE诊断依据国际疾病分类第10版标准。
  • MHT组与非MHT组SLE风险HR 1.114(95%CI 0.88-1.41)。
  • 替勃龙使用3年以内者SLE风险HR 1.45(95%CI 1.051-2.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This retrospective cohort study aimed to investigate the influence of menopausal hormone therapy (MHT) on the occurrence of systemic lupus erythematosus (SLE) in postmenopausal women. Additionally, the study aimed to examine the specific effects of individual MHT drugs. METHODS: In this population-based cohort study conducted in Korea, a total of 452,124 women aged >40 years seeking healthcare for menopause were assessed from January 1, 2011, to December 31, 2014. After employing propensity score matching, 139,331 pairs were included in the MHT and non-MHT groups. Follow-up of participants continued until December 31, 2020. The diagnosis of SLE was based on the International Classification of Diseases 10th edition criteria. RESULTS: The median follow-up in the study was 7.9 [6.9-8.9] years. SLE developed in 134 (0.1 %) of the 139,197 participants in the MHT group and 143 (0.1 %) of the 139,188 of the non-MHT group, individually. The risk of SLE in the MHT group did not show a significant increase compared to the non-MHT group {hazard ratio (HR) 1.114, 95 % confidence interval (CI) 0.88-1.41}. Subgroup analysis results indicated no significant differences based on the type of MHT or the duration of MHT use, except tibolone. In the group that used tibolone within 3 years, the HR for SLE risk was 1.45 (95 % confidence interval: 1.051-2.001). CONCLUSION: The utilization of MHT did not demonstrate a substantial impact on the development of SLE in postmenopausal women. Caution is required in the early stages of tibolone use.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kim JH, Im YH, Noh JH, et al. The effects of menopausal hormone therapy for the risk of systemic lupus erythematosus: A nationwide cohort study in Korea. Semin Arthritis Rheum. 2025. PMID: 39919486. doi:10.1016/j.semarthrit.2025.152632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。